Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

PURPOSE: The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METH...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Abu-Sbeih, Hamzah, Faleck, David M., Ricciuti, Biagio, Mendelsohn, Robin B., Naqash, Abdul R., Cohen, Justine V., Sellers, Maclean C., Balaji, Aanika, Ben-Betzalel, Guy, Hajir, Ibraheim, Zhang, Jiajia, Awad, Mark M., Leonardi, Giulia C., Johnson, Douglas B., Pinato, David J., Owen, Dwight H., Weiss, Sarah A., Lamberti, Giuseppe, Lythgoe, Mark P., Manuzzi, Lisa, Arnold, Christina, Qiao, Wei, Naidoo, Jarushka, Markel, Gal, Powell, Nick, Yeung, Sai-Ching J., Sharon, Elad, Dougan, Michael, Wang, Yinghong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2020
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7030892/
https://ncbi.nlm.nih.gov/pubmed/31800340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01674
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak